11.01
+9.23%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sight Sciences
From its filings with the US Securities and Exchange Commission
Sight Sciences is based in Menlo Park, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SGHT. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $77.4m and a net loss of $38.4m. At that date it held total assets of $115.3m and shareholders' equity of $63.9m. By business, Surgical Glaucoma. brought in 97.9% of revenue, followed by Dry eye. at 2.1%.
Our mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing. We are passionate about improving patients’ lives by helping them to preserve their sight. Our business philosophy is grounded in the following principles: comprehensively understanding disease physiology; developing transformative technologies that are intended to preserve, protect, and restore natural physiological functionality to diseased eyes; developing and marketing products with proven clinical evidence that achieve superior effectiveness versus current treatment paradigms while minimizing complications or side effects; providing intuitive, patient-friendly, interventional solutions to eye care professionals ("ECPs"); and delivering compelling economic value to all stakeholders, including patients, providers and third-party payors such as Medicare and commercial insurers. Our objective is to develop and market products for use in new treatment paradigms and to create an interventional mindset in eyecare whereby our technologies may be used in procedures which supplant conventional outdated approaches.
Quoted from its 10-K, filed 4 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 15 Jul 2021
- Employees
- 186
- Website
- sightsciences.com ↗
- Head office
- 4040 CAMPBELL AVE,, MENLO PARK, CA, 94025
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Staffan EncrantzIndependent Chairman of the Board$213,500
- Mr. Paul BadawiPresident, Chief Executive Officer, Co-Founder, Director, since 2019$3.0m
- Dr. David BadawiCo-Founder, Chief Technology Officer, Director, since 2011
- Mr. Jim RodbergChief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Treasurer
- Ms. Alison BauerleinChief Operating Officer, Principal Operating Officer$2.2m
- Dr. Manohar RahejaExecutive Vice President - Research and Development
- Mr. Brenton TaylorExecutive Vice President - Operations
- Mr. Jeremy HaydenChief Legal Officer$1.5m
- Mr. Gerhard BurbachIndependent Director
- Dr. Tamara FountainIndependent Director$175,000
- Ms. Catherine MazzaccoIndependent Director$182,000
- Mr. Donald ZurbayIndependent Director$187,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 67
- Environment
- 40
- Social
- 99
- Governance
- 61
- Direct emissions (scope 1)
- 7.655 t
- Energy emissions (scope 2)
- 32.038 t
- Value chain emissions (scope 3)
- 2,169.524 t
- Women in the workforce
- 50.5%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sight Sciences Inc has a strong portfolio of innovative medical devices and technologies.
- The company has a dedicated research and development team focused on advancing ophthalmic solutions.
- Sight Sciences Inc enjoys a positive reputation within the industry for its high-quality products.
Weaknesses
- The company might face challenges in terms of regulatory approval for its products in certain regions.
- Sight Sciences Inc may have limited market presence and brand awareness compared to some competitors.
- The company's financial resources and funding may be a limitation for extensive market expansion.
Opportunities
- The growing global prevalence of eye diseases and disorders presents a significant opportunity for Sight Sciences Inc to expand its market share.
- There is an increasing demand for minimally invasive ophthalmic procedures, creating an opportunity for the company's innovative technologies.
- Sight Sciences Inc can explore strategic collaborations and partnerships to enhance its product offerings and market reach.
Threats
- Intense competition within the ophthalmic industry poses a threat to Sight Sciences Inc's market position.
- Regulatory changes and compliance requirements can impact the company's ability to launch and sell its products.
- Economic fluctuations and uncertain healthcare reimbursement policies may affect the affordability and adoption of Sight Sciences Inc's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.